Sulthiame in childhood epilepsy

Bruria Ben-Zeev, Nathan Watemberg, Pinchas Lerman, Itshak Barash, Nathan Brand, Tally Lerman-Sagie

Research output: Contribution to journalReview articlepeer-review


Background: Sulthiame is a central carbonic anhydrase inhibitor found to be effective for both partial and generalized seizures. It has been in use in some European countries and in Israel for over 30 years. The aim of the present study was to evaluate the efficacy and tolerability of sulthiame in childhood epilepsy by conducting a multicenter, retrospective study of patients who received this drug. Methods: The charts of 125 consecutive epilepsy patients treated with sulthiame as monotherapy or add-on therapy were reviewed. Results: Twenty-nine out of 39 patients with benign focal epilepsy of childhood became seizure-free. Total seizure control was also achieved in 17 of 42 patients with symptomatic, non-refractory localization-related epilepsy, and in all 10 cases with juvenile myoclonic epilepsy. Complete normalization of the EEG occurred in 13 of 20 patients with benign partial epilepy of childhood. Side-effects were minimal and caused discontinuation of treatment in only seven children. Conclusion: The high tolerability, efficacy, convenience of use and low cost suggest that sulthiame should become a first line drug in the benign partial epilepsies of childhood and juvenile myoclonic epilepsy. It also has a role as add-on treatment in other partial and myoclonic epilepsies.

Original languageEnglish
Pages (from-to)521-524
Number of pages4
JournalPediatrics International
Issue number5
StatePublished - Oct 2004


  • Antiepileptic drugs
  • Benign partial epilepsy of childhood
  • Epilepsy
  • Juvenile myoclonic epilepsy
  • Sulthiame


Dive into the research topics of 'Sulthiame in childhood epilepsy'. Together they form a unique fingerprint.

Cite this